Reply to the editor:  by Robicsek, Francis
5. Katz MR, Bonatti JO. Totally endoscopic
coronary artery bypass grafting on the ar-
rested heart. Heart Surg Forum. 2007;10:
E338-43.
doi:10.1016/j.jtcvs.2008.02.056
Simultaneous hybrid coronary
revascularization reduces
postoperative morbidity
compared with results from
conventional off-pump coronary
artery bypass
To the Editor:
This study describes a single-center experi-
ence with hybrid procedures in a small pa-
tient group of 15 hybrid patients compared
with a group of 30 matched off-pump pa-
tients. The study has 2 major shortcomings
I want to address. First, the grafts used dif-
fered between the patients because vein
grafts, bilateral internal thoracic arteries,
and radial arteries were used. The choice
of graft influences patency, as well as poten-
tial blood loss. Second, the blood loss in
their off-pump group was rather high
(.1000 mL). Third, and most important,
the quality of revascularization remains an
issue in stent implantation. Although the au-
thors tried to address this, they used the
wrong method because computed tomo-
graphic angiography does not allow for suf-
ficient detection of in-stent restenosis.
Additionally, the group sizes are too small
to allow for a determination of a trend to-
ward better 1-year graft patency; a single
stent occlusion would turn the whole trend.
Finally, off-pump coronary artery bypass
does not require occlusion of coronary ar-
teries for 8 to 12 minutes for each anastomo-
sis; by inserting a shunt, which is standard in
most centers, this occlusion can be reduced
to less than 1 minute. For these reasons,
the conclusions drawn from the results of
this study are that the hybrid procedure is
possible, even with good clinical long-term
results. The study does not provide suffi-
cient data to prove any superiority of the hy-
brid approach compared with the off-pump
coronary artery bypass procedure with com-
plete surgical revascularization.
Helmut Gulbins, MD
Department of Cardiovascular Surgery
University Hospital Eppendorf
University Heart Center
Hamburg, Germany
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Reply to the Editor:
A small single-center study cannot provide
definitive answers to any of the important
questions posed by Dr Gulbins. We agree
that our data do not support the conclusion
that the hybrid approach is superior to the
off-pump coronary artery bypass (OP-
CAB) procedure. An important goal of
this article is merely to provoke debate
about how innovations such as this might
be used to improve the results for surgical
revascularization.
There is no question that differences in
clinical outcomes between the 2 groups
were driven by variables other than the use
of a small thoracotomy instead of a median
sternotomy. For example, differences in the
choice of conduits undoubtedly influenced
outcome. A key advantage of the hybrid
procedure is the use of percutaneous coro-
nary intervention/stenting as a means of
avoiding the well-known shortcomings of
saphenous vein grafts that is used in more
than 95% of coronary artery bypass grafting
procedures done through a sternotomy.
Computed tomographic angiographic fol-
low-up is not adequate to detect in-stent
restenosis, but the use of coated stents ac-
cording to the entry criteria of our study
minimized the expected risk of this problem
to less than 10% in our cohort.1 The risk of
thrombosis is increased with these types of
stents, but thrombosis has a dramatic pre-
sentation that can be reliably diagnosed by
clinical means. Therefore the advantages
provided by the use of invasive angiography
instead of computed tomographic angiogra-
phy for investigating the benefits of using
stents versus the saphenous vein graft in
our cohort would have been modest.
We agree that the blood loss in the
OPCAB group was higher than has been
reported by other groups. This might have
reflected a more rigorous assessment of in-
traoperative losses, including the volume
of blood retrieved by the cell saver; weigh-
ing of sponges; and estimation of other los-
ses. It also might reflect a higher-risk
population of patients than have been en-
rolled in prior OPCAB analyses. Nonethe-
less, the blood loss and rate of transfusions
for the minimally invasive group was
clearly less than has been reported in most
other OPCAB reports.2
Letters to the EditorReply to the editor:
I appreciate the earnest comments of my
colleagues.
Evidently, we see the potentials of tele-
robotics in a different perspective. They
believe not only that robotics is the future
of cardiac surgery, but also that the future
is already here! I respectfully disagree.
They kindly recall my role as an ‘‘inno-
vator.’’ With my 12 patents (the last one
in 2008), I would not deny it. However, I
was also the one who, as the invited discus-
sant to the first lecture of Andreas Gruntzig,
stated that coronary balloon angioplasty will
have an unacceptable recurrence rate, and I
also proved soon after its introduction that
aortic balloon valvuloplasty will be a disas-
ter. To be an innovator means not to
‘‘change’’ but to change toward the better.
In today’s era of evidence-based medi-
cine, the rules of innovation are strict. In-
formed consent is not a nebulous concept
anymore. The margins of clinic and industry
are better defined. Novel methods must un-
dergo intense scrutiny not only from a clini-
cal standpoint but also from an ethical and
economic aspect. Because results of telero-
botics might have reached, but certainly
did not exceed, those obtained with simpler
minimally invasive methods and because
telerobotics has definite marketing under-
tones, with its costs now exceeding a billion
dollars in equipment alone, we are obligated
to ask specific questions. In my editorial I
was asking these questions with an open
mind but also with a healthy dose of old-
fashioned skepticism.
The closing words of my editorial were
these:
Elements of robotics could indeed be
part of the future technology of mini-
mally invasive cardiac interventions.
The proper way to proceed with this
endeavor however, is not to flood
the market with billions of dollars
worth of hardware, most of it already
obsolete, but to limit their use to a few
centers with sincere professional in-
terest, until in well-controlled trials,
the technology proves itself econom-
ically sound, as well as clinically
superior to that which we already
have today.238 The Journal of Thoracic and CardiovThe proof is on you, gentlemen.
Francis Robicsek, MD, PhD
Carolinas Heart and Vascular Institute
Carolinas Medical Center
Charlotte, NC
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